Vanguard Group Inc lessened its stake in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 572,701 shares of the company’s stock after selling 7,904 shares during the period. Vanguard Group Inc owned about 1.92% of Axsome Therapeutics worth $1,976,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Alethea Capital Management LLC increased its holdings in Axsome Therapeutics by 102.1% during the third quarter. Alethea Capital Management LLC now owns 547,443 shares of the company’s stock worth $1,889,000 after buying an additional 276,620 shares during the last quarter. Sio Capital Management LLC increased its holdings in Axsome Therapeutics by 115.5% during the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock worth $1,437,000 after buying an additional 223,168 shares during the last quarter. Finally, Worth Venture Partners LLC purchased a new stake in Axsome Therapeutics during the third quarter worth about $138,000. Institutional investors and hedge funds own 13.00% of the company’s stock.

A number of analysts recently issued reports on AXSM shares. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Axsome Therapeutics in a report on Monday, January 14th. ValuEngine upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. BTIG Research raised their price objective on shares of Axsome Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Tuesday, January 8th. Cantor Fitzgerald set a $16.00 price objective on shares of Axsome Therapeutics and gave the stock a “buy” rating in a report on Monday, December 10th. Finally, Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.00.

AXSM opened at $9.33 on Friday. The stock has a market capitalization of $278.16 million, a PE ratio of -7.52 and a beta of 3.41. The company has a debt-to-equity ratio of 6.00, a current ratio of 1.46 and a quick ratio of 1.46. Axsome Therapeutics Inc has a twelve month low of $1.94 and a twelve month high of $10.80.

TRADEMARK VIOLATION NOTICE: “Axsome Therapeutics Inc (AXSM) Shares Sold by Vanguard Group Inc” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/axsome-therapeutics-inc-axsm-shares-sold-by-vanguard-group-inc/2828076.html.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Featured Story: Initial Public Offering (IPO)

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics Inc (NASDAQ:AXSM).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.